CPC Class C12Q

Provided are systems and methods for plant stress mitigation. The systems provided comprises three key components to perform a self-standardized algorithm for identifying/measuring significant stress conditions within a short time window (for example 1 to 3 days). After identification of a significant stress condition, plants under stress can be treated with a composition comprising an ethylene synthesis or perception inhibitor, for example 1-methylcyclopropene (1-MCP). Also provided are methods for identifying plant genes in response to stress using the system disclosed herein.

The present invention relates to a Lactuca sativa seed designated 79-279 RZ, which exhibits a combination of traits including resistance against downy mildew (Bremia lactucae) races Bl:1 to Bl:32 and Ca-I to Ca-VIII, currant-lettuce aphid (Nasonovia ribisnigri) biotype Nr:0, very small plant size, slight to moderate blistering of the leaves, as well as a multi-leaf trait. The present invention also relates to a Lactuca sativa plant produced by growing the 79-279 RZ seed. The invention further relates to methods for producing the lettuce cultivar, represented by lettuce variety 79-279 RZ.

Eight new sweet basil (Ocimum basilicum L.) cultivars designated ‘Rutgers Thunderstruck-DMR’, ‘Rutgers Passion-DMR’, Rutgers Obsession-DMR’, ‘Rutgers Devotion-DMR’, ‘26_24_33’, ‘50_03_05’, ‘50_03_34’, and ‘42_21_02’ are provided, as are parts of the plants, extracts and biomasses from the variety, and uses thereof, for example as a food or in a food product. These plants have basil downy mildew resistance/tolerance.

The invention relates to the C-terminal fragment of angiopoietin-related protein 4 [cAngptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia.

Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.